Raipur: Medical experts at AIIMS Raipur have called for a comprehensive national effort to boost organ donation in India, ...

CRISPR Therapeutics AG CRSP shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

A red quarter of a circle with the words 'The Quarter Mark' beside it. A year-long series looking back on the most significant moments of the past 25 years, how they changed our world, and how they ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

If you have been staring at CRISPR Therapeutics stock lately, wondering whether it is time to buy, hold, or rethink your position, you are far from alone. Over the past week, the stock has surged 16.1 ...

Lozano is a rare disease mom, neuroscience Ph.D. candidate at UC Davis, and board member for the PURA Syndrome Foundation. In May, a historic moment in science and medicine was captured in a single ...

The rings of DNA inside mitochondria are inaccessible to these techniques, which means that precise edits to mitochondrial DNA (mtDNA) remain frustratingly out of reach. “Mitochondria missed the ...

Who is the Antichrist, the biblical antagonist whose rise marks the beginning of the end-times? Peter Thiel recently took a stab at answering this age-old question. Thiel kicks off the lecture series ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A small S.F. biotech with ties ...

Please provide your email address to receive an email when new articles are posted on . A CRISPR-Cas9-based therapy reduced transthyretin levels in patients with hereditary amyloidosis and ...

Fintel reports that on October 10, 2025, Needham reiterated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 11.29% Upside As of September 30, ...